|
Resistance to anti-tuberculosis drugs stratified by previous tuberculosis treatment and for patients infected with a Beijing or a non-Beijing strain. |
||||||
| New cases |
Previously treated |
Total |
Beijing |
Non-Beijing |
OR (Beijing) (95% CI) |
|
|
|
||||||
| Total cases |
198 |
184 |
382 |
190 |
192 |
|
| Resistance to: |
||||||
| Ethambutol |
14 (7%) |
47 (26%) |
61 (16%) |
49 (26%) |
12 (6%) |
5.2 (2.6–10.8) |
| Rifampicin |
15 (8%) |
54 (30%) |
69 (18%) |
51 (27%) |
18 (9%) |
3.6 (1.9–6.6) |
| Pyrazinamide |
6 (3%) |
24 (13%) |
30 (8%) |
22 (12%) |
8 (4%) |
3.0 (1.2–7.6) |
| Streptomycin |
68 (3%) |
111 (60%) |
179 (47%) |
114 (60%) |
65 (34%) |
2.9 (1.9–4.6) |
| Isoniazid |
47 (24%) |
108 (59%) |
155 (41%) |
99 (52%) |
56 (29%) |
2.6 (1.7–4.1) |
| MDR-TB |
15 (8%) |
53 (29%) |
68 (18%) |
51 (27%) |
17 (9%) |
3.8 (2.0–7.1) |
Cox et al. Respiratory Research 2005 6:134 doi:10.1186/1465-9921-6-134 |
||||||